SCHEMBL5229558

SCHEMBL5229558

CCN(c1cccc(C)c1)S(=O)(=O)Cl

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.58
POLB P06746 3/20 0.57
ALDH1A1 P00352 5/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
GLA P06280 1/20 0.54
ALOX15 P16050 1/20 0.54
LMNA P02545 3/20 0.52
TP53 P04637 3/20 0.52
GAA P10253 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NPC1 O15118 1/20 0.50
KMT2A Q03164 3/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
RECQL P46063 1/20 0.48
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2696214 0.84 POLB (0.61) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL8558804 0.83 HTT (0.55) HTTPOLBALDH1A1HPGDHSD17B10
Cyclopropane SCHEMBL27934850 0.79 HTT (0.51) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL27934849 0.76 HTT (0.49) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL9018871 0.75 DRD2 (0.44) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL11585057 0.73 ALDH1A1 (0.82) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL28649489 0.72 ALDH1A1 (0.46) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL10211704 0.71 ALDH1A1 (0.51) HTTPOLBALDH1A1HPGDHSD17B10
SCHEMBL30565134 0.71 ALDH1A1 (0.61) HTTALDH1A1HPGDHSD17B10ALOX15
SCHEMBL457496 0.71 ALDH1A1 (0.61) HTTALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 HTT 2870/4885POLB 4200/4885ALDH1A1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.